ArticleBMC psychiatry2026
The prevalence of antipsychotic polypharmacy and its associations with violent behaviors among forensic psychiatry patients.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEffective control of psychotic symptoms and behavioral problems is crucial in forensic psychiatric settings to enhance recovery and manage different risk concerns. While antipsychotic polypharmacy is commonly employed to ensure symptom control and risk mitigation, there is limited research on its burden and relationship with violent and aggressive behaviors in forensic psychiatric populations.
objectivesThis study aims to examine the prevalence of antipsychotic polypharmacy among forensic psychiatry patients in Ontario and assess its relationship with recent incidents of aggression and violence.
methodsWe conducted a retrospective analysis using a database prepared from data captured in annual reports submitted to the Ontario Review Board by 12 forensic programs in Canada. We utilized statistical analyses based on negative binomial regression to evaluate associations between antipsychotic polypharmacy and incidences of violence.
resultsAmong 1,104 patients in the databases, 37.8% (n = 417) were on antipsychotic polypharmacy. The most frequent combination was with Olanzapine or Quetiapine. Antipsychotic polypharmacy was more likely among individuals with increased incidents of physical violence to objects (adjusted incidence rate ratio [IRR]: 1.69; 95% Confidence Interval [CI]: 1.07–2.68; p = 0.025), self-harm (IRR: 3.30; 95% CI: 1.29–8.44; p = 0.013), and sexually inappropriate behavior (IRR: 2.43; 95% CI: 1.35–4.36; p = 0.003) and aggression (IRR: 1.57; 95% CI = 1.10–2.27; p = 0.014).
conclusionsAntipsychotic polypharmacy is prevalent among forensic psychiatry patients, and more likely among those with violent and aggressive behaviors. These findings underscore the need for innovative approaches and further research to inform clinical guidelines, thereby improving patient safety and treatment efficacy. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.